Wednesday, August 26, 2026
60 articles analyzed
Updated Aug 26, 10:40 AM · 60 sources analyzed
Key Takeaways
BMS's mavacamten Phase 3 in non-obstructive HCM is complete; data disclosure could unlock a significantly larger addressable market than the current obstructive indication.
Ionis's CARDIO-TTRansform Phase 3 for eplontersen in ATTR-CM is complete; results will determine its competitive position against entrenched tafamidis.
AbbVie's long-term emraclidine safety study in schizophrenia was terminated with no disclosed reason, raising questions about the asset's development trajectory post-Cerevel acquisition.
🏆 Winner
Camurus AB — Phase 3 of CAM2029 in acromegaly completed, positioning the company for a potential regulatory filing with a differentiated self-administered formulation
📉 Loser
AbbVie — termination of the emraclidine long-term safety extension in schizophrenia is an unexplained setback for a high-value Cerevel acquisition asset
🔭 Watch Next
BMS is expected to present full mavacamten Phase 3 data in non-obstructive HCM at a major cardiology meeting, most likely AHA in November 2026, which will be the pivotal event for the Camzyos franchise expansion.
BMS completes Phase 3 of mavacamten in non-obstructive HCM
Bristol-Myers Squibb's Phase 3 trial of mavacamten (Camzyos) in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM — a form of the disease where the heart's outflow tract is not physically blocked) has reached completed status on ClinicalTrials.gov. The current approved label covers obstructive HCM only, making this trial the key data package needed to pursue a label expansion into the larger nHCM population. If the data support efficacy, BMS would have a meaningful opportunity to grow the Camzyos franchise well beyond its current addressable market.
ClinicalTrials.gov ↗Bristol-Myers Squibb
Mavacamten (Camzyos) in Non-obstructive hypertrophic cardiomyopathy (nHCM)
The trial (NCT05582395) has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released; the registry update reflects study completion status only.
Why it matters
The completion of this Phase 3 registry entry sets the stage for what will be the most consequential data readout in the Camzyos story to date — nHCM represents the bigger unmet need and a harder efficacy bar than the obstructive form. BMS will need to show meaningful functional improvement to justify a label expansion and fend off pipeline competitors in the myosin inhibitor space.
What to watch
Watch for BMS to present full efficacy and safety data at a major cardiology conference — likely AHA 2026 in November — and any subsequent supplemental NDA filing timeline.
Ionis Pharmaceuticals
Eplontersen (formerly ION-682884) in Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
The CARDIO-TTRansform trial (NCT04136171) has been marked Completed on ClinicalTrials.gov. Efficacy and safety outcome data from this readout have not been released through the registry update.
Why it matters
Eplontersen already holds approval for ATTR polyneuropathy, but the cardiomyopathy indication is the larger prize — competing directly against Pfizer's tafamidis and Alnylam's patisiran/vutrisiran. The investment thesis hinges on whether CARDIO-TTRansform data can demonstrate a cardiovascular mortality or morbidity benefit convincing enough to shift prescribing patterns in a market where tafamidis is entrenched.
What to watch
Watch for Ionis and AstraZeneca to disclose CARDIO-TTRansform topline results and an sNDA filing timeline, likely in H2 2026 or early 2027.
Small-molecule CD28 inhibitor shows selective T-cell suppression in IBD models
A bioRxiv preprint reports that a small molecule identified via NanoBiT split-luciferase screening selectively inhibits CD28 costimulation (a signal that activates inflammatory T cells) in inflammatory bowel disease models, without simultaneously blocking CTLA-4 signaling — a limitation of current antibody-based B7 blockade approaches.
Why it matters
This is early-stage preprint science, but the mechanistic rationale is compelling for BD teams in autoimmune: selectively dialing down pathogenic T-cell activation without broadly suppressing regulatory T cells is one of the field's harder engineering problems. If selectivity holds in in vivo models, this could attract partnership interest from larger immunology platforms.
What to watch
Watch for peer review publication and any follow-up in vivo efficacy data; if the researchers advance to IND-enabling studies, this could become an acquisition or licensing target within 12–18 months.
AbbVie's emraclidine long-term safety study in schizophrenia terminated
A Phase 2 long-term safety and tolerability study of emraclidine (CVL-231), AbbVie's M4 muscarinic receptor agonist for schizophrenia, has been marked Terminated on ClinicalTrials.gov (NCT05443724); no reason for termination is disclosed in the registry.
Why it matters
AbbVie acquired emraclidine through its Cerevel Therapeutics deal, paying a substantial premium for the pipeline. A terminated safety extension — even absent a disclosed reason — is a yellow flag for the asset's regulatory readiness and puts pressure on AbbVie to clarify the development path publicly. Karuna/BMS's KarXT (xanomeline-trospium), now approved, has already validated the muscarinic mechanism; the question is whether emraclidine can differentiate.
What to watch
Watch for AbbVie to provide any pipeline update on emraclidine at its next earnings call or R&D day, and whether the Phase 3 program remains on track.
The trial (NCT05582395) has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released; the registry update reflects study completion status only.
Why it matters
Mavacamten is already approved for obstructive HCM; a successful nHCM data package would open a substantially larger patient population and extend the franchise lifecycle.
Analysis
The completion of this Phase 3 registry entry sets the stage for what will be the most consequential data readout in the Camzyos story to date — nHCM represents the bigger unmet need and a harder efficacy bar than the obstructive form. BMS will need to show meaningful functional improvement to justify a label expansion and fend off pipeline competitors in the myosin inhibitor space.
What to watch
Watch for BMS to present full efficacy and safety data at a major cardiology conference — likely AHA 2026 in November — and any subsequent supplemental NDA filing timeline.
The CARDIO-TTRansform trial (NCT04136171) has been marked Completed on ClinicalTrials.gov. Efficacy and safety outcome data from this readout have not been released through the registry update.
Why it matters
ATTR-CM is a crowded and commercially high-stakes space; eplontersen's Phase 3 completion positions Ionis and AstraZeneca (commercialization partner) to pursue a potential label expansion or regulatory submission in cardiomyopathy beyond the existing polyneuropathy indication.
Analysis
Eplontersen already holds approval for ATTR polyneuropathy, but the cardiomyopathy indication is the larger prize — competing directly against Pfizer's tafamidis and Alnylam's patisiran/vutrisiran. The investment thesis hinges on whether CARDIO-TTRansform data can demonstrate a cardiovascular mortality or morbidity benefit convincing enough to shift prescribing patterns in a market where tafamidis is entrenched.
What to watch
Watch for Ionis and AstraZeneca to disclose CARDIO-TTRansform topline results and an sNDA filing timeline, likely in H2 2026 or early 2027.
The Phase 3 trial (NCT04076462) evaluating CAM2029 versus placebo in acromegaly has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released through the registry.
Why it matters
CAM2029 is a self-administered subcutaneous formulation designed to replace monthly clinic visits for somatostatin analogue injections — a meaningful convenience advantage if efficacy holds up versus standard-of-care lanreotide or octreotide LAR.
Analysis
Camurus is a smaller European biotech where acromegaly represents a near-term commercial inflection point. Completion of the Phase 3 puts the company in position to file for approval, but actual data disclosure will determine whether CAM2029 can differentiate on both efficacy and the patient-convenience story it has been building.
What to watch
Watch for Camurus to disclose topline Phase 3 results and any regulatory submission plans in Europe or the US in the coming months.
The Phase 3 trial (NCT05869903) of oral orforglipron in adults with obesity or overweight has been marked Active, Not Recruiting on ClinicalTrials.gov. No efficacy or safety data have been released through the registry update.
Why it matters
Oral GLP-1 receptor agonists are one of the most commercially contested spaces in pharma; orforglipron's non-peptide, fully oral profile would differentiate it from semaglutide tablets (Rybelsus) if Phase 3 weight-loss data are competitive.
Analysis
Lilly's entire oral obesity franchise thesis rests on orforglipron delivering weight loss in the 15–20% body weight range that injectable GLP-1s have set as the new commercial benchmark. Enrollment completion is a necessary but not sufficient milestone — investors will not move the needle until topline efficacy data are disclosed.
What to watch
Watch for Lilly to announce topline Phase 3 results for orforglipron in obesity, which the company has guided toward a 2026 readout.
An open-label extension study (NCT06179875) for non-responders from Viridian's Phase 2/3 VRDN-001 trials has been marked Completed on ClinicalTrials.gov. Efficacy and safety outcome data have not been released through the registry update.
Why it matters
Viridian is competing directly with Amgen/Horizon's teprotumumab (Tepezza) in TED; an OLE focused on non-responders is a targeted strategy to capture patients who fail the current standard of care, which could support a differentiated label claim.
Analysis
The OLE completion for non-responders is a small but strategically telling data point — Viridian is building an evidence base around patients underserved by teprotumumab, which is the right commercial positioning for a second entrant in a market with a well-entrenched first mover. The value of this completion depends entirely on what the data show.
What to watch
Watch for Viridian to disclose OLE results and any regulatory filing update for VRDN-001 in TED in the second half of 2026.
Small-molecule CD28 inhibitor shows selective T-cell suppression in IBD models
A bioRxiv preprint reports that a small molecule identified via NanoBiT split-luciferase screening selectively inhibits CD28 costimulation (a signal that activates inflammatory T cells) in inflammatory bowel disease models, without simultaneously blocking CTLA-4 signaling — a limitation of current antibody-based B7 blockade approaches.
Why it matters
A CD28-selective oral small molecule could offer a cleaner immunosuppressive profile than existing biologics in IBD, potentially avoiding the immunological complications associated with CTLA-4 interference and opening a path to oral dosing in a class currently dominated by injectables.
Analysis
This is early-stage preprint science, but the mechanistic rationale is compelling for BD teams in autoimmune: selectively dialing down pathogenic T-cell activation without broadly suppressing regulatory T cells is one of the field's harder engineering problems. If selectivity holds in in vivo models, this could attract partnership interest from larger immunology platforms.
What to watch
Watch for peer review publication and any follow-up in vivo efficacy data; if the researchers advance to IND-enabling studies, this could become an acquisition or licensing target within 12–18 months.
AbbVie's emraclidine long-term safety study in schizophrenia terminated
A Phase 2 long-term safety and tolerability study of emraclidine (CVL-231), AbbVie's M4 muscarinic receptor agonist for schizophrenia, has been marked Terminated on ClinicalTrials.gov (NCT05443724); no reason for termination is disclosed in the registry.
Why it matters
Emraclidine's development path in schizophrenia warrants scrutiny — a terminated long-term safety extension raises questions about whether tolerability findings, enrollment challenges, or a strategic portfolio reassessment drove the decision, with implications for the broader muscarinic agonist class.
Analysis
AbbVie acquired emraclidine through its Cerevel Therapeutics deal, paying a substantial premium for the pipeline. A terminated safety extension — even absent a disclosed reason — is a yellow flag for the asset's regulatory readiness and puts pressure on AbbVie to clarify the development path publicly. Karuna/BMS's KarXT (xanomeline-trospium), now approved, has already validated the muscarinic mechanism; the question is whether emraclidine can differentiate.
What to watch
Watch for AbbVie to provide any pipeline update on emraclidine at its next earnings call or R&D day, and whether the Phase 3 program remains on track.
Pfizer Phase 3 hemophilia A/B study with PF-06741086 marked completed
Pfizer's Phase 3 trial (NCT03938792) of PF-06741086, an anti-TFPI (tissue factor pathway inhibitor) antibody for severe hemophilia A and moderately severe-to-severe hemophilia B, has been marked Completed on ClinicalTrials.gov with no efficacy data disclosed through the registry.
Why it matters
Anti-TFPI antibodies represent a non-factor replacement approach to hemophilia that could work across both A and B subtypes regardless of inhibitor status — a potential differentiator in a market being rapidly reshaped by gene therapy and fitusiran.
Analysis
Pfizer is playing catch-up in hemophilia after the setbacks to its gene therapy program; completion of this Phase 3 is a pipeline milestone, but the asset's commercial viability will depend on a clean safety profile — anti-TFPI agents have previously faced thrombotic risk concerns — and competitive positioning against an increasingly crowded non-factor space.
What to watch
Watch for Pfizer to disclose Phase 3 topline results and any NDA/BLA filing plans for PF-06741086, likely in H2 2026 or 2027.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Erasca filed an 8-K with the SEC disclosing Item 8.01 on August 24, 2026. The filing type (8.01 covers other material events) suggests a reportable development, but the content of the disclosure is not detailed in the available source and cannot be independently characterized without additional information.
SEC EDGAR ↗Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse